
ARES · NYSE
Consensus is Buy across 14 analysts, with a mean price target of $149. The supplied consensus does not report a low or high target, so the target spread cannot be measured and the most- and least-bullish analysts cannot be identified. No analyst-specific target changes or rating revisions are provided for the past week, leaving the direction of revisions undetermined. The substantive disagreement visible in the evidence is between improving operating momentum—record fundraising, higher fee-paying AUM, and double-digit growth in fee-related earnings—and the quarter’s 4.16% revenue miss. That contrast, rather than a documented target revision, explains the available debate.